Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and the fund's risk resistance by 2029 [2] Drug and Device Approvals - Zai Lab has received approval for clinical trials of injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [4] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [5] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the last 30 trading days [7] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [8] Industry Events - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the medical insurance catalog for 2025, with 6,537 being medical institutions and 4,592 retail pharmacies [10][11] - France has launched a roadmap to address national obesity issues, setting four key objectives to curb obesity growth and improve health outcomes [12] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for misleading statements in its restructuring plan, leading to a 20% drop in its stock price [14]

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and fund risk resistance by 2029 [1] Drug and Device Approvals - Zai Lab has received clinical trial approval for injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [2] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [3] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the previous 30 trading days [4] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [5] Industry Developments - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the 2025 medical insurance catalog, with 6,537 being medical institutions and 4,592 retail pharmacies [6][7] - France has launched a roadmap for addressing national obesity issues, with goals to curb obesity growth, improve health conditions, enhance accessibility to personalized medical services, and support innovative care methods from 2026 to 2030 [8] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for alleged misleading statements in its restructuring plan, leading to a 20% drop in its stock price [9]

Core Insights - The National Healthcare Security Administration (NHSA) is facilitating the implementation of negotiated drugs in the 2025 medical insurance catalog, providing a list of new negotiated drugs and innovative commercial insurance drugs for 2025 [1][2] Group 1: New Drug Distribution - As of January 11, 2026, 105 new negotiated drugs have been included in the medical insurance catalog, distributed across 11,129 designated medical institutions nationwide [1] - Among the 105 new negotiated drugs, 88 have available distribution information, with two drugs, namely Increlex and Liposomal Irinotecan, available in all 31 provinces and the Xinjiang Production and Construction Corps [1] - 20 drugs are available in more than 30 provinces, 53 drugs in more than 20 provinces, and 67 drugs in more than 10 provinces [1] Group 2: Commercial Insurance Drugs - There are 19 innovative commercial insurance drugs, with 16 having distribution information, and the drug Ipilimumab is available in over 30 provinces [1] - Seven commercial insurance drugs are distributed in more than 20 provinces, and 12 drugs are available in more than 10 provinces [1] Group 3: Monitoring and Compliance - The NHSA will focus on monitoring drugs that have not yet been distributed to designated medical institutions, ensuring that companies comply with distribution requirements to protect the medication rights of insured individuals [2]